Abstract
Novel rhodium, iridium, and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anticancer agents. The complexes show promising cytotoxicities, with the presence, position, and number of halides having a significant effect on the corresponding IC50 values. One ruthenium complex was found to be more cytotoxic than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively, and it remains active with MCF-7 cells even under hypoxic conditions, making it a promising candidate for in vivo studies.
| Original language | English |
|---|---|
| Pages (from-to) | 727-736 |
| Number of pages | 10 |
| Journal | Inorganic Chemistry |
| Volume | 53 |
| Issue number | 2 |
| Early online date | 7 Jan 2014 |
| DOIs | |
| Publication status | Published - 21 Jan 2014 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Rhodium, iridium, and ruthenium half-sandwich picolinamide complexes as anticancer agents'. Together they form a unique fingerprint.Profiles
-
Andrew Hebden
- Department of Design and Architecture - Research Fellow in Technical Textiles
- School of Applied Sciences
Person: Academic
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver